Towards Data-Driven Science Literacy: Extracting Psycholinguistic Markers in Vaping-Related Online Peer Interactions.

Respiratory syncytial virus (RSV) is the most common viral cause of lower respiratory tract infection (LRTI) and bronchiolitis in infants and young children, resulting in approximately 2.1 million outpatient visits and 58,000–80,000 hospitalizations annually among children in the United States (US) younger than 5 years old. Globally, RSV infects more than 60% of children in their first year of life and nearly all children will be infected with RSV by 2 years of age. Given the burden and severity of RSV infection, particularly among infants and young children, the development of novel prevention and treatment strategies has been an ongoing priority. Immunization with an RSV monoclonal antibody (mAb) for infants and young children was approved by the US Food and Drug Administration (FDA) in July 2023 and, the next month, was recommended by the Advisory Committee on Immunization Practice (ACIP) for immunization of infants up to 8 months old born during or entering their first RSV season and for infants and children aged 8–19 months at increased risk for severe RSV disease and entering their second RSV season. Soon after, following FDA approval, ACIP recommended seasonal administration of a one-time dose of an RSV prefusion (RSVPreF) vaccine (Abrysvo, Pfizer Inc.) to pregnant persons at 32–36 weeks of gestation for the prevention of RSV-associated LRTI in infants aged <6 months. Prior to regulatory approval and availability in the US, we surveyed adult participants in a community-based cohort study to examine likelihood of accepting either infant mAb or a maternal RSV vaccine and the factors that contribute to vaccination. We also describe parental awareness of and perceived risk related to RSV infection, confidence in sources of information about RSV, and preferences for infant RSV mAb and maternal RSV vaccine.